![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BIOVAIL LAUNCHES WELLBUTRIN XL TO CANADIAN PHYSICIANS
BIOVAIL LAUNCHES WELLBUTRIN XL TO CANADIAN PHYSICIANS
April 12, 2006
Biovail Corporation announced
today that Wellbutrin XL, the first once-daily extended-release formulation of
bupropion hydrochloride approved for the Canadian market for the treatment of
depression in adults, has been officially launched and is commercially available.
Wellbutrin XL, is being marketed and distributed by Biovail Pharmaceuticals Canada
(BPC), the Canadian sales and marketing division of Biovail Corporation. Wellbutrin
XL, which received a Notice of Compliance from the Therapeutic Products Directorate
(Canada) in January 2006, is available in 150mg and 300mg dosage strengths.
CCN
Matthews
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct